Compare Sanmina Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 12,249 Million (Small Cap)
39.00
NA
0.00%
0.31
12.64%
4.95
Revenue and Profits:
Net Sales:
4,013 Million
(Quarterly Results - Mar 2026)
Net Profit:
98 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
59.26%
0%
59.26%
6 Months
38.28%
0%
38.28%
1 Year
203.11%
0%
203.11%
2 Years
275.2%
0%
275.2%
3 Years
353.09%
0%
353.09%
4 Years
484.82%
0%
484.82%
5 Years
472.89%
0%
472.89%
Sanmina Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.25%
EBIT Growth (5y)
9.12%
EBIT to Interest (avg)
13.83
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
3.03
Tax Ratio
21.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
21.19%
ROE (avg)
13.67%
Valuation key factors
Factor
Value
P/E Ratio
39
Industry P/E
Price to Book Value
4.95
EV to EBIT
30.77
EV to EBITDA
23.66
EV to Capital Employed
4.03
EV to Sales
1.40
PEG Ratio
1.87
Dividend Yield
NA
ROCE (Latest)
13.08%
ROE (Latest)
12.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 96 Schemes (59.94%)
Foreign Institutions
Held by 155 Foreign Institutions (9.4%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
4,013.30
3,189.70
25.82%
Operating Profit (PBDIT) excl Other Income
277.50
157.20
76.53%
Interest
32.10
24.70
29.96%
Exceptional Items
-73.40
-44.00
-66.82%
Consolidate Net Profit
97.80
51.80
88.80%
Operating Profit Margin (Excl OI)
57.40%
36.90%
2.05%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 25.82% vs 52.15% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 88.80% vs -0.38% in Dec 2025
Annual Results Snapshot (Consolidated) - Sep'25
Sep'25
Sep'24
Change(%)
Net Sales
8,128.40
7,568.30
7.40%
Operating Profit (PBDIT) excl Other Income
514.50
468.10
9.91%
Interest
20.20
29.20
-30.82%
Exceptional Items
-40.50
-10.20
-297.06%
Consolidate Net Profit
266.30
237.80
11.98%
Operating Profit Margin (Excl OI)
48.60%
45.70%
0.29%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2025 is 7.40% vs -15.30% in Sep 2024
Consolidated Net Profit
YoY Growth in year ended Sep 2025 is 11.98% vs -27.39% in Sep 2024
About Sanmina Corp. 
Sanmina Corp.
Pharmaceuticals & Biotechnology
Sanmina Corporation is a provider of integrated manufacturing solutions, components, products and repair, logistics and after-market services. The Company provides its offerings primarily to original equipment manufacturers (OEMs) in various industries, including communications networks, storage, industrial, defense and aerospace, medical and energy. The Company operates through two businesses: Integrated Manufacturing Solutions (IMS) and Components, Products and Services (CPS). IMS consists of printed circuit board assembly and test, final system assembly and test, and direct-order-fulfillment. Its Components include interconnect systems and mechanical systems. Its Products include memory, radio frequency (RF), optical and microelectronics solutions, defense and aerospace products, storage solutions and cloud-based manufacturing execution software. Its Services include design, engineering, logistics and repair services.






